Mizuho notes that during Wave Life Sciences’ ongoing R&D day, the company is presenting obesity slides, noting that INHBE knockdown led to 16% lower body weight and that INHBE reduction leads to significant decrease in visceral fat at 5 weeks. The firm has a Buy rating and $10 price target on Wave Life Sciences shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on WVE:
- Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
- Wave Life Sciences to hold a virtual analyst and investor R&D day
- Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
- Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”